Instil Bio, Inc.TILEarnings & Financial Report
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
Revenue
$2.2M
Gross Profit
N/A
Operating Profit
$-15.0M
Net Profit
$-13.6M
Gross Margin
N/A
Operating Margin
-670.0%
Net Margin
-606.0%
YoY Growth
50.2%
EPS
$-2.01
Instil Bio, Inc. Q3 FY2025 Financial Summary
Instil Bio, Inc. reported revenue of $2.2M (up 50.2% YoY) for Q3 FY2025, with a net profit of $-13.6M (up 41.0% YoY) (-606.0% margin).
Key Financial Metrics
| Total Revenue | $2.2M |
|---|---|
| Net Profit | $-13.6M |
| Gross Margin | N/A |
| Operating Margin | -670.0% |
| Report Period | Q3 FY2025 |
Instil Bio, Inc. Annual Revenue by Year
Instil Bio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.0M |
| 2024 | $4.3M |
Instil Bio, Inc. Quarterly Revenue & Net Profit History
Instil Bio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.2M | -19.2% | $-8.2M | -365.3% |
| Q3 FY2025 | $2.2M | +50.2% | $-13.6M | -606.0% |
| Q2 FY2025 | $2.2M | — | $-21.4M | -954.2% |
| Q1 FY2025 | $2.2M | — | $-28.2M | -1257.8% |
| Q4 FY2024 | $2.8M | — | $-11.9M | -428.8% |
| Q3 FY2024 | $1.5M | — | $-23.0M | -1541.9% |
| Q2 FY2024 | $0 | — | $-14.9M | N/A |
| Q1 FY2024 | $0 | — | $-24.3M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.5M | $2.8M | $2.2M | $2.2M | $2.2M | $2.2M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | 50.2% | -19.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $306.3M | $294.3M | $272.6M | $263.6M | $237.4M | $231.0M | $211.8M | $203.5M |
| Liabilities | $100.5M | $99.3M | $96.2M | $94.1M | $92.5M | $99.3M | $91.3M | $89.7M |
| Equity | $205.8M | $195.0M | $176.3M | $169.4M | $144.9M | $131.7M | $120.4M | $113.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.4M | $-10.6M | $-20.1M | $-10.6M | $-4.2M | $-14.8M | $-10.6M | $-7.1M |